Results 51 to 60 of about 4,958,167 (188)

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

Movement Disorders, Volume 41, Issue 6, Page 1492-1501, June 2026.
Complement activation is implicated in Huntington's disease; ANX005 is a potent inhibitor of component C1q. ANX005 exhibited a generally manageable safety profile with rapid reduction in C1q in the cerebrospinal fluid. Functional ability on composite Unified Huntington's Disease Rating Scale and total functional capacity was maintained, with potential ...
Rajeev Kumar, Pinky Agarwal, Karen Anderson, Daniel Claassen, Marissa Dean, Andrew Duker, Burton Scott, Benjamin Hoehn, Ann Mongan, Ping Lin, Ellen Cahir‐McFarland, Lori Taylor, Glenn Morrison, Ted Yednock, Sanjay Keswani, Henk‐Andre Kroon   +15 more
wiley   +1 more source

Medical devices for restless legs syndrome – clinical utility of the Relaxis pad

Therapeutics and Clinical Risk Management, 2015
Ulrike H Mitchell Department of Exercise Sciences, Brigham Young University, Provo, UT, USA Abstract: Restless Legs Syndrome or Willis–Ekbom Disease, a neurosensory disorder, can be treated with pharmaceuticals or conservatively.
Mitchell UH
doaj  

Epileptic–Dyskinetic Encephalopathy Associated with a PPP3CA Variant: Expansion of the Phenotypic Spectrum

Movement Disorders Clinical Practice, EarlyView.
Bruno Antunes Contrucci, Ursula Thomé, Larissa Aparecida Batista, Ana Laura Volpi Martins Lorenzoni, Carla Andrea Cardoso Tanuri Caldas, Americo Ceiki Sakamoto, Israel Gomy, Lisandra Mesquita Batista, Marcela Lopes de Almeida, Ana Paula Andrade Hamad, Guillermo Andrey Ariza Traslaviña   +10 more
wiley   +1 more source

When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions

Movement Disorders, Volume 41, Issue 6, Page 1337-1348, June 2026.
Abstract Although Parkinson's disease (PD) is classically defined by its motor features, non‐motor symptoms exert a substantial and often under‐recognized influence on disease trajectory. Among these, weight loss has long been observed in PD and other neurodegenerative disorders, yet the mechanisms remain incompletely understood.
Ellie D. Gabriel, Robert S. Eisinger, Joyce M. Lee, Sarah Hamimi, Hope Kim, Susanna D. Howard, Casey H. Halpern   +6 more
wiley   +1 more source

Restless legs syndrome/Willis–Ekbom disease prevalence in beta thalassemia patients [PDF]

Sleep and Breathing, 2017
Both beta thalassemia and restless legs syndrome (RLS) patients share some common pathophysiological characteristics related to iron handling. In the present study, the aim was to explore the prevalence of RLS as well as to explore potential association between the syndrome and various quality of life-related parameters in a sample of beta thalassemia ...
Dimitriadou, Euthimia, Giannaki, Christoforos D., Tsekoura, Maria, Stefanidis, Ioannis, Hadjigeorgiou, Georgios M., Lavdas, Eleftherios, Karatzaferi, Christina, Sakkas, Giorgos K.   +7 more
openaire   +3 more sources

Phenotypic Clues in Infantile‐Onset Parkinsonism‐Dystonia‐2: A Treatable Neurotransmitter Disorder

Movement Disorders Clinical Practice, Volume 13, Issue 9, Page 2288-2292, September 2026.
Sangeetha Yoganathan, Haya S. AlFaris, Lindsey Vogt, Michele Eid, Anika Menetrey, Sayoni Roy Chowdhury, Dawn Codeiro, Pradeep Krishnan, Liali Aljouda, Emily W.Y. Tam, Carolina Gorodetsky   +10 more
wiley   +1 more source

Types of Pain in Multiple System Atrophy

Movement Disorders, Volume 41, Issue 5, Page 1221-1232, May 2026.
Abstract Background Pain affects up to 87% of people with multiple system atrophy (MSA), but it remains unclear which types of pain contribute most to the overall burden. Objective To estimate the frequency of different types of pain in MSA individuals.
Nicole Campese, Mubasher A. Qamar, Maria Alexandra Chiriac, Georg Göbel, Julia Wanschitz, Andreas Schlager, Bianca Caliò, Fabian Leys, Pam Bower, Laura Zamarian, Anette Schrag, Roy Freeman, Horacio Kaufmann, Roberta Granata, Stefan Kiechl, Werner Poewe, Klaus Seppi, Gregor Wenning, K. Ray Chaudhuri, Alessandra Fanciulli   +19 more
wiley   +1 more source

Development and Validation of a Brief Fall Questionnaire (FALL‐HD) for Patients with Huntington's Disease

Movement Disorders Clinical Practice, Volume 13, Issue 4, Page 949-955, April 2026.
ABSTRACT Background Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a mutation in the huntingtin gene on chromosome 4, leading to progressive cognitive decline, motor impairment, and functional disability. Falls represent the leading cause of nursing home placement in HD.
Japleen Kaur, Deng‐Yuan Liou, Krisha Bagga, Nadeen Youhanan, Andrew Hall, Paul E. Gilbert, Daniel J. Goble, Jody Corey‐Bloom   +7 more
wiley   +1 more source

Arts Syndrome and Involuntary Eye Movements

Movement Disorders Clinical Practice, Volume 13, Issue 8, Page 1997-1999, August 2026.
Victor Rebelo Procaci, Victor Augusto Vanderlinde Camara, Flavio Moura Rezende Filho, José Luiz Pedroso, Orlando Graziani Povoas Barsottini   +4 more
wiley   +1 more source

Clinical Algorithm‐Guided Approach to Botulinum Toxin Type A Treatment for Axial Postural Abnormalities in Parkinson's Disease

Movement Disorders Clinical Practice, Volume 13, Issue 4, Page 985-995, April 2026.
Abstract Background Axial postural abnormalities (APAs) are common, disabling complications of Parkinson's disease (PD) with unclear pathophysiology. The presence of hyperactivity in multiple trunk muscles supports the use of botulinum toxin (BTA). However, its application is complex, due to the lack of standardized clinical and electrophysiological ...
Giacomo Argenziano, Giovanna Squintani, Serena Camozzi, Ilaria Di Vico, Marialuisa Gandolfi, Carlo Alberto Artusi, Michele Tinazzi, Christian Geroin   +7 more
wiley   +1 more source